Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience
- PMID: 20643091
- DOI: 10.1016/j.vaccine.2010.07.010
Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience
Abstract
In response to the pandemic H1N1 influenza 2009 outbreak, many jurisdictions undertook mass immunization programs that were among the largest in recent history. The objective of this study was to determine the cost-effectiveness of the mass H1N1 immunization program in Ontario, Canada's most populous province (population 13,000,000). This analysis suggests that a mass immunization program as carried out in Ontario and many other high-income health care systems in response to H1N1 2009 was effective in preventing influenza cases and health care resource use and was also highly cost-effective despite the substantial program cost.
(c) 2010 Elsevier Ltd. All rights reserved.
Comment in
-
Cost-effectiveness of Ontario's pandemic vaccine program.Vaccine. 2011 May 17;29(22):3829; author reply 3830-1. doi: 10.1016/j.vaccine.2010.08.089. Epub 2010 Sep 8. Vaccine. 2011. PMID: 20831912 No abstract available.
Similar articles
-
Pandemic (H1N1) 2009 influenza vaccine roll-out in NSW.N S W Public Health Bull. 2010 Jan-Feb;21(1-2):32-5. doi: 10.1071/NB09039. N S W Public Health Bull. 2010. PMID: 20374692
-
Vaccines against influenza A (H1N1) pandemic.Arch Med Res. 2009 Nov;40(8):693-704. doi: 10.1016/j.arcmed.2009.10.008. Arch Med Res. 2009. PMID: 20304259
-
Summaries for patients. Assessing the best way to prevent spread of influenza.Ann Intern Med. 2009 Dec 15;151(12):I31. doi: 10.7326/0003-4819-151-12-200912150-00161. Ann Intern Med. 2009. PMID: 20008744 No abstract available.
-
Immunization-safety monitoring systems for the 2009 H1N1 monovalent influenza vaccination program.Pediatrics. 2011 May;127 Suppl 1:S78-86. doi: 10.1542/peds.2010-1722L. Epub 2011 Apr 18. Pediatrics. 2011. PMID: 21502251 Review.
-
2009 pandemic influenza: a review.Curr Opin Pediatr. 2010 Aug;22(4):530-5. doi: 10.1097/MOP.0b013e32833bb81a. Curr Opin Pediatr. 2010. PMID: 20601883 Review.
Cited by
-
Economic evaluations of vaccines in Canada: a scoping review.Cost Eff Resour Alloc. 2017 May 5;15:7. doi: 10.1186/s12962-017-0069-4. eCollection 2017. Cost Eff Resour Alloc. 2017. PMID: 28484344 Free PMC article.
-
Costs and benefits of interventions aimed at major infectious disease threats: lessons from the literature.Eur J Health Econ. 2020 Dec;21(9):1329-1350. doi: 10.1007/s10198-020-01218-4. Epub 2020 Aug 13. Eur J Health Econ. 2020. PMID: 32789780 Free PMC article. Review.
-
COVID-19 During Development: A Matter of Concern.Front Cell Dev Biol. 2021 Apr 7;9:659032. doi: 10.3389/fcell.2021.659032. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33898461 Free PMC article.
-
Pandemic (H1N1) 2009: assessing the response.CMAJ. 2010 Nov 23;182(17):1874-8. doi: 10.1503/cmaj.100900. Epub 2010 Oct 18. CMAJ. 2010. PMID: 20956501 Free PMC article. No abstract available.
-
Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--2.Value Health. 2012 Sep-Oct;15(6):804-11. doi: 10.1016/j.jval.2012.06.016. Value Health. 2012. PMID: 22999129 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical